{"title": "Clinical trials", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2021-09-15", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "|E.1 Medical condition or disease under investigation\n|\n|E.1.1||Medical condition(s) being investigated ||\n|\n|COVID19 vaccine in kidney transplant patients\n|\n|Vacuna COVID19 en pacientes trasplantados renales\n|\n|E.1.1.1||Medical condition in easily understood language ||\n|\n|COVID19 vaccine in kidney transplant patients\n|\n|Vacuna COVID19 en pacientes trasplantados renales\n|\n|E.1.1.2||Therapeutic area ||Diseases [C] - Virus Diseases [C02]\n|\n|MedDRA Classification\n|\n|E.1.2 Medical condition or disease under investigation\n|\n|\n|\n|E.1.2||Version ||23.1\n|\n|E.1.2||Level ||LLT\n|\n|E.1.2||Classification code ||10084464\n|\n|E.1.2||Term ||COVID-19 immunization\n|\n|E.1.2||System Organ Class ||100000004865\n|\n|E.1.2 Medical condition or disease under investigation\n|\n|\n|\n|E.1.2||Version ||23.1\n|\n|E.1.2||Level ||LLT\n|\n|E.1.2||Classification code ||10084465\n|\n|E.1.2||Term ||COVID-19 vaccination\n|\n|E.1.2||System Organ Class ||100000004865\n|\n|E.1.3||Condition being studied is a rare disease || No\n|\n|E.2 Objective of the trial\n|\n|E.2.1||Main objective of the trial ||\n|\n|The objective will be to analyze the development of cellular and humoral immunity against SARS-CoV-2 after administration of a third dose of mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full standard (two-dose) regimen.\n|\n|El objetivo ser\u00e1 el de analizar el desarrollo de inmunidad celular y humoral frente a SARS-CoV-2 tras la administraci\u00f3n de una tercera dosis de la vacuna mRNA-1273 (Moderna) en pacientes que han permanecido seronegativos tras la pauta est\u00e1ndar completa (dos dosis).\n|\n|E.2.2||Secondary objectives of the trial ||\n|\n|- To analyse the development of cellular and humoral immunity against SARS-CoV-2 after 4 months of administration of a third dose of mRNA-1273 vaccine (Moderna).\n|\n- To establish baseline factors associated with biological non-response to vaccination.\n- To assess the safety and tolerability of the administration of the third dose of mRNA-1273 (Moderna) vaccine.\n|\u2022Analizar el desarrollo de inmunidad celular y humoral frente a SARS-CoV-2 tras 4 meses de la administraci\u00f3n de una tercera dosis de la vacuna mRNA-1273 (Moderna).\n|\n\u2022Establecer factores basales asociados a la no respuesta biol\u00f3gica a la vacunaci\u00f3n.\n\u2022Evaluar la seguridad y tolerabilidad de la administraci\u00f3n de la tercera dosis de la vacuna mRNA-1273 (Moderna).\n|E.2.3||Trial contains a sub-study || No\n|\n|E.3||Principal inclusion criteria ||\n|\n|1. Age > 18 years;\n|\n2. Male or female sex;\n3. Renal transplant with stable renal function in the last 2 months prior to study inclusion;\n4.Had received a full schedule of vaccination for SARS-CoV-2 with mRNA1273 vaccine (Moderna) and remained seronegative at 2 weeks after the second dose.\n5.Patient giving written informed consent.\n|1.Edad > 18 a\u00f1os;\n|\n2.Sexo masculino o femenino;\n3.Trasplante renal con funci\u00f3n renal estable en los \u00faltimos 2 meses previamente a la inclusi\u00f3n en el estudio;\n4.Haber recibido pauta completa de vacunaci\u00f3n para SARS-CoV-2 con la vacuna mRNA1273 (Moderna) y haber permanecido seronegativos a las 2 semanas despu\u00e9s de la segunda dosis.\n5.Paciente que otorgue el consentimiento informado por escrito\n|E.4||Principal exclusion criteria||\n|\n|1. Renal transplantation < 3 months;\n|\n2. Pregnancy or lactation status;\n3. Rejection treated within the last 6 months;\n4. Presence of humoral immunity to SARS-CoV-2 defined as the presence of specific IgM/IgG.\n|1.Trasplante renal < 3 meses;\n|\n2.Estado de embarazo o lactancia;\n3.Rechazo tratado en los \u00faltimos 6 meses;\n4.Presencia de inmunidad humoral frente al SARS-CoV-2 definida como presencia de IgM/IgG espec\u00edficas.\n|E.5 End points\n|\n|E.5.1||Primary end point(s)||\n|\n|The primary endpoint of the study is to assess biological effectiveness by:\n|\n- Total antibody and IgG before (day 0) and after administration of the third dose (week +2).\n- ELISpot of T-cells subjected to SARS-CoV-2 antigenic stimulus before (day 0) and after administration of the third dose (week +2)\n|La variable principal del estudio es evaluar la efectividad biol\u00f3gica mediante:\n|\n\u2022T\u00edtulo anticuerpos totales e IgG antes (d\u00eda 0) y despu\u00e9s de la administraci\u00f3n de la tercera dosis (semana +2).\n\u2022ELISpot de c\u00e9lulas T sometidas a est\u00edmulo antig\u00e9nicos de SARS-CoV-2 antes (d\u00eda 0) y despu\u00e9s de la administraci\u00f3n de la tercera dosis (semana +2);\n|E.5.1.1||Timepoint(s) of evaluation of this end point||\n|\n|day 0 and week +2\n|\n|D\u00eda 0 y semana +2\n|\n|E.5.2||Secondary end point(s)||\n|\n|- Total antibody and IgG at 4 months after the third dose.\n|\n- ELISpot of T-cells subjected to SARS-CoV-2 antigenic stimulus at 4 months after receiving the third dose.\n- Analysis of baseline factors associated with biological non-response to vaccination, including demographics, comorbidities, and transplant-associated factors:\nage, sex, diabetes, type of transplant (kidney-pancreas versus kidney), treatment with anti-thymocyte globulins (ATG) during the last year, lymphopenia defined as < 1000/mm3, time from transplantation < 1 year, eGFR (CKD-EPI), baseline immunosuppression, according to individual drug or the combination received by the patient, type of donor, BMI, ethnicity and blood type.\n- Percentage of patients with mild and/or severe adverse events after administration of the third dose.\n|\u2022T\u00edtulo anticuerpos totales e IgG a los 4 meses tras recibir la tercera dosis.\n|\n\u2022ELISpot de c\u00e9lulas T sometidas a est\u00edmulo antig\u00e9nicos de SARS-CoV-2 a los 4 meses tras recibir la tercera dosis.\n\u2022An\u00e1lisis de los factores basales asociados a la no respuesta biol\u00f3gica a la vacunaci\u00f3n, incluyendo factores demogr\u00e1ficos, comorbilidades, y asociados al trasplante:\nSexo\nTipo de trasplante (renal / renopancre\u00e1tico)\nTratamiento con globulinas antitimoc\u00edticas durante el \u00faltimo a\u00f1o\nLimfopenia definida como < 1000/mm3\nTiempo del trasplante < 1 a\u00f1o\neGFR (CKD-EPI)\ninmunosupresion basal de acuerdo al tratamiento recibido por el paciente, tipo de donante, BMI, etnia y grupo sanguineo.\n\u2022Porcentaje de pacientes que presentan acontecimientos adversos leves y/o graves tras la administraci\u00f3n de la tercera dosis\n|E.5.2.1||Timepoint(s) of evaluation of this end point||\n|\n|E.6 and E.7 Scope of the trial\n|\n|E.6||Scope of the trial\n|\n|E.6.1||Diagnosis|| No\n|\n|E.6.2||Prophylaxis|| Yes\n|\n|E.6.3||Therapy|| No\n|\n|E.6.4||Safety|| No\n|\n|E.6.5||Efficacy|| No\n|\n|E.6.6||Pharmacokinetic|| No\n|\n|E.6.7||Pharmacodynamic|| No\n|\n|E.6.8||Bioequivalence|| No\n|\n|E.6.9||Dose response|| No\n|\n|E.6.10||Pharmacogenetic|| No\n|\n|E.6.11||Pharmacogenomic|| No\n|\n|E.6.12||Pharmacoeconomic|| No\n|\n|E.6.13||Others|| No\n|\n|E.7||Trial type and phase\n|\n|E.7.1||Human pharmacology (Phase I)|| No\n|\n|E.7.1.1||First administration to humans|| No\n|\n|E.7.1.2||Bioequivalence study|| No\n|\n|E.7.1.3||Other|| No\n|\n|E.7.1.3.1||Other trial type description||\n|\n|E.7.2||Therapeutic exploratory (Phase II)|| Yes\n|\n|E.7.3||Therapeutic confirmatory (Phase III)|| No\n|\n|E.7.4||Therapeutic use (Phase IV)|| No\n|\n|E.8 Design of the trial\n|\n|E.8.1||Controlled|| No\n|\n|E.8.1.1||Randomised|| No\n|\n|E.8.1.2||Open|| Yes\n|\n|E.8.1.3||Single blind|| No\n|\n|E.8.1.4||Double blind || No\n|\n|E.8.1.5||Parallel group|| No\n|\n|E.8.1.6||Cross over || No\n|\n|E.8.1.7||Other|| No\n|\n|E.8.2|| Comparator of controlled trial\n|\n|E.8.2.1||Other medicinal product(s)|| No\n|\n|E.8.2.2||Placebo || No\n|\n|E.8.2.3||Other|| No\n|\n|E.8.3||\nThe trial involves single site in the Member State concerned\n|| Yes\n|\n|E.8.4|| The trial involves multiple sites in the Member State concerned || No\n|\n|E.8.5||The trial involves multiple Member States|| No\n|\n|E.8.6 Trial involving sites outside the EEA\n|\n|E.8.6.1||Trial being conducted both within and outside the EEA|| No\n|\n|E.8.6.2||Trial being conducted completely outside of the EEA|| No\n|\n|E.8.7||Trial has a data monitoring committee|| No\n|\n|E.8.8||\nDefinition of the end of the trial and justification where it is not the last\nvisit of the last subject undergoing the trial\n||\n|\n|E.8.9 Initial estimate of the duration of the trial\n|\n|E.8.9.1||In the Member State concerned years||\n|\n|E.8.9.1||In the Member State concerned months||\n|\n|E.8.9.1||In the Member State concerned days||\n|", "language": null, "image": null, "pagetype": null, "links": ["/help.html", "/ctr-search/search", "/joiningtrial.html", "/contacts.html", "/about.html", "/about.html", "/whatsNew.html", "/dataquality.html", "/doc/Sponsor_Contact_Information_EUCTR.pdf", "/natauthorities.html", "/links.html", "/index.html", "/about.html", "https://euclinicaltrials.eu/", "https://eudract.ema.europa.eu/docs/guidance/EudraCT%20FAQ_for%20publication.pdf", "/doc/How_to_Search_EU_CTR.pdf#zoom=100,0,0", "javascript:void(0)", "javascript:void(0)", "#", "javascript:$('#expand').click();window.print()", "javascript:void(0)", null, "javascript:window.location.replace('#A')", "javascript:window.location.replace('#B')", "javascript:window.location.replace('#C')", "javascript:window.location.replace('#D')", "javascript:window.location.replace('#D8')", "javascript:window.location.replace('#E')", "javascript:window.location.replace('#F')", "javascript:window.location.replace('#G')", "javascript:window.location.replace('#N')", "javascript:window.location.replace('#P')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", "https://eudract.ema.europa.eu/contact.html", "/disclaimer.html", "https://euclinicaltrials.eu/", "http://www.ema.europa.eu", "http://www.hma.eu"]}